CONFIDENTIAL PORTIONS HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”).** NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • May 5th, 2020 • California
This NON-EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made as of October 22, 2013 (the “Effective Date”) by and between Advanced Inhalation Therapies (AIT) Ltd., a company incorporated under the laws of the State of Israel (“Licensee”), and SensorMedics Corporation, a California corporation (“CareFusion”).
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • October 6th, 2022 • Colorado
This License Agreement (hereinafter “Agreement”), which shall be effective on the date it is executed by the last Party to sign (the “Effective Date”), below is between Alliance for Sustainable Energy, LLC (hereinafter "Alliance"), Management and Operating Contractor for the National Renewable Energy Laboratory (hereinafter “NREL”) located at 15013 Denver West Parkway., Golden, Colorado 80401 and [COMPANY NAME], (hereinafter "Licensee"), a for-profit company organized and existing under the laws of the State of [NAME of STATE] and having a principal place of business at [COMPANY ADDRESS], hereinafter referred to individually as “Party” and jointly as “Parties”. This Agreement shall be effective on the date the last Party signs this Agreement (hereinafter “Effective Date”).
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • June 28th, 2018 • BioNano Genomics, Inc • Laboratory analytical instruments
This non-exclusive patent license agreement (“Agreement”), by and between Q Biotechnology C.V. (“Licensor”), a Dutch company with a place of business at Spoorstraat 50, 5911 KJ Venlo, the Netherlands and BioNano Genomics, Inc (“Licensee”), a Delaware (USA) corporation with a place of business at 9640 Town Centre Drive, Suite 100, San Diego, CA 92121, USA is made effective as of May 1st, 2014 (“Effective Date”).
EX-10.33 36 d782664dex1033.htm EX-10.33 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 AMENDMENT to the NON- EXCLUSIVE PATENT LICENSE...Non-Exclusive Patent License Agreement • May 5th, 2020
NON-EXCLUSIVE PATENT LICENSE AGREEMENT FOR DISC PRODUCT MANUFACTURERSNon-Exclusive Patent License Agreement • March 14th, 2000 • Future Media Productions • Phonograph records & prerecorded audio tapes & disks • New York
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • May 15th, 2009 • MDRNA, Inc. • Pharmaceutical preparations • New Jersey
THIS NON-EXCLUSIVE PATENT LICENSE AGREEMENT (“Agreement”), effective as of February 12, 2009 (“Effective Date”) is by and between, on the one hand, Hoffmann-La Roche Inc. with a place of business at 340 Kingsland Street, Nutley, New Jersey 07110 and F. Hoffmann-La Roche Ltd with a place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (collectively “Roche”) and, on the other hand, MDRNA, Inc. with a place of business at 3830 Monte Villa Parkway, Bothell, Washington 98021 (“MDRNA”). Roche and MDRNA are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • October 21st, 2019 • Oyster Point Pharma, Inc. • Biological products, (no disgnostic substances) • New York
This Non-Exclusive Patent License Agreement (the “Agreement”) is made as of 18th October 2019 (the “Effective Date”) by and between Pfizer Inc. a corporation organized under the laws of Delaware, having its principal place of business at 235 East 42nd Street, New York, NY 10017, USA (hereinafter “Pfizer”) on behalf of itself and its Affiliates, and Oyster Point Pharma, Inc. a corporation organized and existing under the laws of Delaware and having offices located at 202 Carnegie Center, Suite 109, Princeton, NJ 08540 (“Oyster”). Each of Oyster and Pfizer may be referred to individually herein as a “Party” or collectively as the “Parties”.
NON-EXCLUSIVE PATENT LICENSE AGREEMENT by and between PACIFIC BEACH BIOSCIENCES, INC andNon-Exclusive Patent License Agreement • July 9th, 2010 • Iaso Pharma Inc • Pharmaceutical preparations • New York
THIS AGREEMENT, effective as of November 4, 2009 (the “Effective Date”), by and between Pacific Beach Biosciences, Inc, a corporation organized and existing under the laws of Delaware with its principal offices at 8910 University Center Lane, Suite 620, San Diego, CA 92122 USA (“PBBio”) and [*].
EX-10.10 9 dex1010.htm NON-EXCLUSIVE PATENT LICENSE AGREEMENT NON-EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN OSMETECH AND THE UNIVERSITY OF WASHINGTON UW REFERENCE: 7063-18921A UW TECHTRANSFER, INVENTION LICENSING NEGOTIATED BY CHRISTINE HAN, PH.D.,...Non-Exclusive Patent License Agreement • May 5th, 2020 • Washington
This Agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effective Date”), and is made by and between the University of Washington, a public institution of higher education and an agency of the state of Washington (the “University”), and Osmetech Molecular Diagnostics, an entity consisting solely of Clinical Micro Sensors, Inc. and Osmetech, Inc., both Delaware Corporations (the “Company”), (individually a “Party” or collectively the “Parties”).
NON-EXCLUSIVE PATENT LICENSE AGREEMENT JOHN D. ERICSSON INVENTOR and SEA PRIDE INDUSTRIES, INC. AND ITS AFFILIATE SUBSIDIARY SEA STAR INDUSTRIES, INC. RE: SEA STAR TM OYSTER RELAY SYSTEM Version: Thursday, June 27, 1996 NON-EXCLUSIVE LICENSE AGREEMENT...Non-Exclusive Patent License Agreement • May 15th, 2000 • Biomarine Technologies Inc
NON-EXCLUSIVE PATENT LICENSE AGREEMENT FOR INTERNAL RESEARCH USENon-Exclusive Patent License Agreement • February 14th, 2013 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Licensed Products, Processes, Territory, Field of Use and Termination), Appendix C (Royalties), Appendix D (Shipping Information) and Appendix E (Royalty Payment Options). The Parties to this Agreement are:
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • June 10th, 2016 • Kadmon Holdings, LLC • Pharmaceutical preparations • New York
THIS NON-EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 20, 2008 (“Effective Date”) by and among Three Rivers Pharmaceuticals LLC, a Pennsylvania limited liability company, (the “Licensor”), Zydus Pharmaceuticals USA, Inc., a New Jersey corporation, and Cadila Healthcare Limited d/b/a Zydus-Cadila, an Indian corporation (collectively, the “Licensee”), Licensor and Licensee are sometimes referred to as the “Parties” and individually as a “Party”.
AMENDMENT to the NON-EXCLUSIVE PATENT LICENSE AGREEMENT dated 01 May 2014 (the “Amendment”)Non-Exclusive Patent License Agreement • May 14th, 2018 • BioNano Genomics, Inc • Laboratory analytical instruments
NON-EXCLUSIVE PATENT LICENSE AGREEMENT MEE Agreement No: [***] MEE Case Nos: [***]Non-Exclusive Patent License Agreement • September 6th, 2019 • Frequency Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Non-Exclusive Patent License Agreement (“Agreement”) is made as of the 7th day of February, 2019 (“Effective Date”), by and between Frequency Therapeutics, Inc., a Delaware corporation, having a principal place of business at 19 Presidential Way, Woburn, MA 01801 (“Company”) and Massachusetts Eye and Ear Infirmary, a not-for-profit Massachusetts corporation, with a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • August 19th, 2009 • MDRNA, Inc. • Pharmaceutical preparations • New Jersey
THIS NON-EXCLUSIVE PATENT LICENSE AGREEMENT (“Agreement”), effective as of February 12, 2009 (“Effective Date”) is by and between, on the one hand, Hoffmann-La Roche Inc. with a place of business at 340 Kingsland Street, Nutley, New Jersey 07110 and F. Hoffmann-La Roche Ltd with a place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (collectively “Roche”) and, on the other hand, MDRNA, Inc. with a place of business at 3830 Monte Villa Parkway, Bothell, Washington 98021 (“MDRNA”). Roche and MDRNA are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
NATIONAL INSTITUTES OF HEALTH NON‑EXCLUSIVE PATENT LICENSE AGREEMENT FOR INTERNAL RESEARCH USE COVER PAGENon‑exclusive Patent License Agreement • August 7th, 2012 • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Licensed Products, Processes, Territory, Field of Use and Termination), Appendix C (Royalties), Appendix D (Shipping Information) and Appendix E (Royalty Payment Options). The Parties to this Agreement are:
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • May 5th, 2020 • Washington
This Agreement is made and entered into between Battelle Memorial Institute, herein called "BATTELLE", having a place of business in Richland, Washington, and
NON-EXCLUSIVE PATENT LICENSE AGREEMENT between MERCK & CO., INC. and REGENERON PHARMACEUTICALS, INC.Non-Exclusive Patent License Agreement • November 12th, 2003 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
THIS AGREEMENT effective as of 18 August, 2003, (the “Effective Date”) between Merck & Co., Inc., a New Jersey corporation (“Merck”) and Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron”).
NON-EXCLUSIVE PATENT LICENSE AGREEMENT by and between PACIFIC BEACH BIOSCIENCES, INC and MERCK SHARP & DOHME CORP.Non-Exclusive Patent License Agreement • December 27th, 2010 • Iaso Pharma Inc • Pharmaceutical preparations • New York
THIS AGREEMENT, effective as of November 4, 2009 (the “Effective Date”), by and between Pacific Beach Biosciences, Inc, a corporation organized and existing under the laws of Delaware with its principal offices at 8910 University Center Lane, Suite 620, San Diego, CA 92122 USA (“PBBio”) and Merck Sharp & Dohme Corp. (“Merck”).
ARTICLE I DEFINITIONSNon-Exclusive Patent License Agreement • March 29th, 2002 • Integrated Security Systems Inc • Communications equipment, nec • Illinois
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • September 22nd, 2010
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Licensed Products, Processes, Territory, Field of Use and Termination), Appendix C (Development Plan). The Parties to this Agreement are:
NON-EXCLUSIVE PATENT LICENSE AGREEMENT BETWEENNon-Exclusive Patent License Agreement • April 30th, 2018 • HyperSciences, Inc. • General industrial machinery & equipment • Washington
This non-exclusive patent license agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effective Date”), and is made between HyperSciences, Inc., a Delaware corporationHSI, (“HSI”), and EnergeticX.net, LLC, a Washington limited liability company (“Company”), (individually “Party” or collectively “Parties”).
NON-EXCLUSIVE PATENT LICENSE AGREEMENT between Mount Sinai Genomics, Inc. and Icahn School of Medicine at Mount SinaiNon-Exclusive Patent License Agreement • July 28th, 2021 • Sema4 Holdings Corp. • Services-health services • New York
This Non-Exclusive Patent License Agreement (this “Agreement”) is by and between Icahn School of Medicine at Mount Sinai, a New York not-for-profit education corporation, with a principal place of business at One Gustave L. Levy Place, New York, NY 10029 (“Mount Sinai”) and Mount Sinai Genomics, Inc., a Delaware corporation with a principal place of business at 1425 Madison Avenue, New York, NY 10029 (“MSGI”). This Agreement will become effective on June 1, 2017, (the “Effective Date”). Mount Sinai and MSGI are individually referred to herein as a “Party” and together as the “Parties”.
NON EXCLUSIVE PATENT LICENSE AGREEMENTNon Exclusive Patent License Agreement • March 14th, 2018
R&D, legal person no. …, with its head office at …, …-… …, represented by …, in his/her capacity as …, with powers for the fact, hereinafter referred to as the R&D or First Party;
NON EXCLUSIVE PATENT LICENSE AGREEMENT (With Comments)Non Exclusive Patent License Agreement • March 14th, 2018
The framework for the M4 agreement is one in which an R&D institution (university, polytechnic, R&D centre, among others, acting as legal entities) grants a non exclusive license to exploit a patent right or a patent pending application to a individual or legal entity of a commercial nature.
Non-Exclusive Patent License AgreementNon-Exclusive Patent License Agreement • November 2nd, 2023 • Acme United Corp • Cutlery, handtools & general hardware
This Agreement is made on this 1st day of November, 2023 (“Effective Date”), between Acme United Corporation, a Connecticut corporation located at 1 Waterview Drive, Suite 200 Shelton, CT 06484 (“Licensor”) and Good Sportsman Marketing, L.L.C., a Delaware limited liability company located at 5250 Frye Road, Irving, TX 75061 (“Licensee”). Licensor and Licensee are each sometimes referred to in this Agreement as a “Party,” and collectively as the “Parties.”
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • September 28th, 2006 • FP Technology, Inc. • Services-advertising • Texas
This Non-Exclusive Patent License Agreement (“this Agreement”), made and entered into this 28th day of March, 2006 (the “Effective Date”), by and between Orion IP, LLC (“Licensor”), a limited liability company organized under the laws of the state of Delaware, and FP Technology Holdings, Inc., a Delaware corporation (“Licensee”) (each a “Party” and collectively the “Parties”).
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • January 31st, 2017 • Texas
This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).
NON-EXCLUSIVE PATENT LICENSE AGREEMENTNon-Exclusive Patent License Agreement • November 28th, 2007 • ImmunoBiotics Inc • Florida
This Non-exclusive Patent License Agreement entered into this 1st day of September, 2007, by and between ImmunoBiotics, Inc., a corporation organized under the laws of the State of Florida, having its principal office at 511 NE 94th Street, Building 2, MiamiShores, Florida 33138, hereinafter referred to as "Licensor," and SYNORx, Inc., a corporation organized under the laws of the State of Nevada, having its principal office at 1060 Calle Negocio, Suite B, San Clemente, California 92673, hereinafter referred to as "Licensee."
ContractNon-Exclusive Patent License Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential.
